First Time Loading...

Moderna Inc
NASDAQ:MRNA

Watchlist Manager
Moderna Inc Logo
Moderna Inc
NASDAQ:MRNA
Watchlist
Price: 107.97 USD 1.69% Market Closed
Updated: Apr 27, 2024
Section:
 

Wall Street
Price Targets

MRNA Price Targets Summary
Moderna Inc

Wall Street analysts forecast MRNA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MRNA is 135 USD with a low forecast of 59.59 USD and a high forecast of 325.5 USD.

MRNA Lowest Forecast
Wall Street Target
59.59 USD
45% Downside
MRNA Average Forecast
Wall Street Target
135 USD
25% Upside
MRNA Highest Forecast
Wall Street Target
325.5 USD
201% Upside
Lowest
Price Target
59.59 USD
45% Downside
Average
Price Target
135 USD
25% Upside
Highest
Price Target
325.5 USD
201% Upside

MRNA Last Price Targets
Moderna Inc

The latest public price target was made on Apr 24, 2024 by Matthew Harrison from Morgan Stanley , who expects MRNA stock to drop by 18% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
Matthew Harrison
Morgan Stanley
89 USD
Downside 18%
3 days ago
Apr 24, 2024
Morgan Stanley Comments on Moderna (MRNA) Collaboration with OpenAI
StreetInsider
Michael Yee
Jefferies
125 USD
Upside 16%
4 weeks ago
Mar 28, 2024
Moderna (MRNA) PT Raised to $125 at Jefferies ahead of RSV launch and CMV data
StreetInsider
Eliana Merle
UBS
143 USD
Upside 32%
1 month ago
Mar 27, 2024
UBS Reiterates Buy Rating on Moderna (MRNA)
StreetInsider
Matthew Harrison
Morgan Stanley
123 USD
Upside 14%
2 months ago
Feb 22, 2024
Moderna Likely To Report Q4 Loss; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Benzinga
Bill Maughan
Canaccord Genuity
82 USD
Downside 24%
2 months ago
Feb 22, 2024
Moderna Likely To Report Q4 Loss; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Benzinga
Hartaj Singh
Oppenheimer
142 USD
Upside 32%
3 months ago
Jan 2, 2024
Moderna Analyst Projects Transformation Into 'Five-Product Commercial Company' By 2026
Benzinga
Eliana Merle
UBS
191 USD
Upside 77%
10 months ago
Jun 26, 2023
Moderna Pipeline For Any Vaccine Beyond Covid Is 'Underappreciated,' Analyst Says
Benzinga
Show More Price Targets
Show Less Price Targets
Matthew Harrison
Morgan Stanley
Price Target 89 USD
Upside/Downside 18%
View Source
Michael Yee
Jefferies
Price Target 125 USD
Upside/Downside 16%
View Source
Eliana Merle
UBS
Price Target 143 USD
Upside/Downside 32%
View Source
Matthew Harrison
Morgan Stanley
Price Target 123 USD
Upside/Downside 14%
View Source
Bill Maughan
Canaccord Genuity
Price Target 82 USD
Upside/Downside 24%
View Source
Hartaj Singh
Oppenheimer
Price Target 142 USD
Upside/Downside 32%
View Source
Eliana Merle
UBS
Price Target 191 USD
Upside/Downside 77%
View Source
Show More Price Targets
Show Less Price Targets
Moderna Inc Competitors:
Price Targets
6855
Ascentage Pharma Group International
85% Upside
PRLD
Prelude Therapeutics Inc
45% Upside
2INV
2Invest AG
72% Downside
E
1952
Everest Medicines Ltd
3% Upside
6855
Ascentage Pharma Group International
85% Upside
PRLD
Prelude Therapeutics Inc
45% Upside
2INV
2Invest AG
72% Downside
E
1952
Everest Medicines Ltd
3% Upside
BIOG B
Biogaia AB
34% Upside
ORY
Oryzon Genomics SA
227% Upside
HARP
Harpoon Therapeutics Inc
8% Upside
BBIO
BridgeBio Pharma Inc
101% Upside

Revenue
Forecast

Revenue Estimate
Moderna Inc

For the last 6 years the compound annual growth rate for Moderna Inc's revenue is 79%. The projected CAGR for the next 3 years is -3%.

79%
Past Growth
-3%
Estimated Growth
Estimates Accuracy
2%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Moderna Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
3%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Moderna Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-5%
Average Miss
What are analyst estimates?

See Also

Summary
MRNA intrinsic value, competitors valuation, and company profile.
DCF Valuation
MRNA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
MRNA stock valuation using valuation multiples.
Wall Street Estimates
MRNA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
MRNA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is MRNA's stock price target?
Price Target
135 USD

According to Wall Street analysts, the average 1-year price target for MRNA is 135 USD with a low forecast of 59.59 USD and a high forecast of 325.5 USD.

What is Moderna Inc's Revenue forecast?
Projected CAGR
-3%

For the last 6 years the compound annual growth rate for Moderna Inc's revenue is 79%. The projected CAGR for the next 3 years is -3%.

ALPHA SPREAD
Join more than 131,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.